Core-shell cisplatin/SiO2 nanocapsules combined with PTC-209 overcome chemotherapy–Acquired and intrinsic resistance in hepatocellular carcinoma
Source abstract
Abstract
The primary cause of cisplatin resistance in liver cancer is reduced intracellular drug accumulation and altered DNA repair/apoptosis signaling. Existing strategies to reverse cisplatin resistance have limited efficacy, as they target individual factors. This study proposes a drug delivery system consisting of a cisplatin core, a silica shell with a tetra-sulfide bond, and a PEG-coated surface (Core/shell-PGCN). The system is designed to consume glutathione (GSH) and reduce cisplatin excretion from cells, thereby overcoming acquired cisplatin resistance. In addition, Core/shell-PGCN incorporates PTC-209 (Core/shell-PGCN@PTC-209), a Bmi1 inhibitor that suppresses liver cancer stem cells (CSC), to mitigate DNA repair/apoptosis signaling and reverse intrinsic cisplatin resistance. In vivo and in vitro results demonstrate that Core/shell-PGCN@PTC-209 can comprehensively regulate GSH and CSC, reverse intrinsic and acquired cisplatin resistance, and enhance the efficacy of cisplatin in treating liver cancer. This "inner cultivation, outer action" approach may offer a new strategy for reversing cisplatin resistance in liver cancer. STATEMENT OF SIGNIFICANCE: Cisplatin resistance is widely observed in liver cancer (HCC) chemotherapy, with two mechanisms identified: acquired and intrinsic. Most strategies aimed at overcoming cisplatin resistance focus on a single perspective. This study introduces a core-shell drug delivery system (DDS) combined with HCC stem cell inhibitors, which can effectively address cisplatin resistance in HCC by targeting both acquisition and internality. Specifically, the core-shell drug delivery system can impede cisplatin efflux by neutralizing the acquired resistance factor (GSH), thus overcoming acquired resistance. Additionally, HCC stem cell inhibitors can reverse intrinsic resistance by inhibiting HCC stem cells. Therefore, this study contributes to the application of DDS in combating drug resistance in HCC and enhances its potential for clinical implementation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Chemotherapy-induced organ toxicity mitigation · Nanoparticle-Based Drug Delivery · Liver physiology and pathology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan10.1038/bjc.2013.542 ↗
2. Molecular mechanisms of cisplatin resistance10.1038/onc.2011.384 ↗
3. Cisplatin: mode of cytotoxic action and molecular basis of resistance10.1038/sj.onc.1206933 ↗
4. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers10.1038/nature06633 ↗
5. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer10.1016/j.ejmech.2022.114205 ↗
6. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles10.1016/j.actbio.2016.09.045 ↗
7. Glutathione metabolism in cancer progression and treatment resistance10.1083/jcb.201804161 ↗
8. Glutathione in cancer biology and therapy10.1080/10408360500523878 ↗
9. Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatin-GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin10.1039/C8RA09652J ↗
10. Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts10.1021/jm900138u ↗
11. Cancer stem cells revisited10.1038/nm.4409 ↗
12. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications10.1038/s41575-021-00508-3 ↗
13. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells10.1016/j.actbio.2023.03.004 ↗
14. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma10.1186/s12943-021-01315-9 ↗
15. N-acetyl-galactosamine modified metal-organic frameworks to inhibit the growth and pulmonary metastasis of liver cancer stem cells through targeted chemotherapy and starvation therapy10.1016/j.actbio.2022.08.027 ↗
16. BMI1 represses Ink4a/Arf and Hox genes to regulate stem cells in the rodent incisor10.1038/ncb2766 ↗
17. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma10.1016/j.ccr.2007.08.032 ↗
18. Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer10.1186/s12943-020-01229-y ↗
19. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer10.1186/s12943-019-0981-7 ↗
20. BMI1 and MEL18 promote colitis-associated cancer in mice via REG3B and STAT310.1053/j.gastro.2017.07.044 ↗
21. BMI1 inhibition eliminates residual cancer stem cells after PD1 blockade and activates antitumor immunity to prevent metastasis and relapse10.1016/j.stem.2020.06.022 ↗
22. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome10.1182/blood.2018890764 ↗
23. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma10.1158/0008-5472.CAN-07-5882 ↗
24. Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling10.1016/j.jhep.2015.05.016 ↗
25. Effect of Bmi-1-mediated NF-kappaB signaling pathway on the stem-like properties of CD133+ human liver cancer cells10.3233/CBM-181329 ↗
26. Self-renewal as a therapeutic target in human colorectal cancer10.1038/nm.3418 ↗
27. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment10.1186/s13045-016-0247-4 ↗
28. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development10.1080/15384101.2018.1469872 ↗
29. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy10.1021/nn403606m ↗
30. Applications of the solvation parameter model in reversed-phase liquid chromatography10.1016/j.chroma.2016.05.099 ↗
31. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging10.1021/ja803777x ↗
32. Ultrasmall oxygen-deficient bimetallic oxide MnWO(X) nanoparticles for depletion of endogenous GSH and enhanced sonodynamic cancer therapy10.1002/adma.201900730 ↗
33. GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma10.1016/j.actbio.2020.06.020 ↗
34. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo10.1016/j.actbio.2019.05.034 ↗
35. An enzyme-engineered nonporous copper(I) coordination polymer nanoplatform for cuproptosis-based synergistic cancer therapy10.1002/adma.202204733 ↗
36. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers10.1016/j.ccell.2018.12.009 ↗
37. Multifunctional nanolocks with GSH as the key for synergistic ferroptosis and anti-chemotherapeutic resistance10.1016/j.biomaterials.2022.121704 ↗
38. Intracellular catalysis with selected metal complexes and metallic nanoparticles: advances toward the development of catalytic metallodrugs10.1021/acs.chemrev.8b00493 ↗
39. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy10.1016/j.biomaterials.2021.121110 ↗
40. Glutathione-responsive nanoparticles of camptothecin prodrug for cancer therapy
41. Glutathione pulse therapy: promote spatiotemporal delivery of reduction-sensitive nanoparticles at the "cellular level" and synergize PD-1 blockade therapy
42. An NIR discrete metallacycle constructed from perylene bisimide and tetraphenylethylene fluorophores for imaging-guided cancer radio-chemotherapy10.1002/adma.202106388 ↗
43. Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy10.1016/j.nantod.2015.09.005 ↗
44. BMI1 is a therapeutic target in recurrent medulloblastoma10.1093/neuonc/nox083.225 ↗
45. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells10.1053/gast.1997.v112.pm9024305 ↗
46. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells10.1038/s41556-018-0140-1 ↗
47. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPalpha expression10.1126/scitranslmed.aad6066 ↗
48. Linc00210 drives Wnt/beta-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner10.1186/s12943-018-0783-3 ↗
49. Identification and characterization of tumorigenic liver cancer stem/progenitor cells10.1053/j.gastro.2007.04.025 ↗
50. Use of nude mouse xenograft models in prostate cancer research10.1002/1097-0045(20000601)43:4<263::AID-PROS5>3.0.CO;2-I ↗
51. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development10.1016/j.ejca.2003.11.028 ↗
52. Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation10.1016/j.jconrel.2020.10.003 ↗
53. Hydrodynamic transfection for generation of novel mouse models for liver cancer research10.1016/j.ajpath.2013.12.002 ↗
54. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans10.1016/j.jhep.2015.10.004 ↗
55. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice10.1053/j.gastro.2014.05.004 ↗